XMD-17-51 TFA

Overview

XMD-17-51 TFA is a pyrimido-diazepinone compound that is able to modulate protein kinases.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Pain | Products > Disease Areas > Digestive System Inflammation | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Cytoskeleton | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Neuronal Signaling | Products > Research Areas > Others | Products > Signaling Pathways > Mps1 | Products > Signaling Pathways > Bcr-Abl | Products > Signaling Pathways > Polo-like Kinase (PLK) | Products > Signaling Pathways > Trk Receptor | Products > Signaling Pathways > ERK | Products > Signaling Pathways > AMPK

Product Information

• Catalog No.: HY-117291A
• CAS No.: 2436579-93-8
• Molecular Formula: C23H25F3N8O3
• Molecular Weight: 518.49
• Purity: 99.46%
• Storage: 4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
• Solubility: ≥ 2.5 mg/mL (4.82 mM); Clear solution
• Availability: In-stock

Source

Original product source